Answers are grounded in this paper and cite their sources.
Letter discusses shingles risk in ulcerative colitis therapies, indicating local factors affect Janus kinase inhibitor safety.
We read with interest the study by Ahuja et al. comparing shingles risk across advanced therapies in inflammatory bowel disease. The authors provide valuable comparative evidence showing a 1.7- to 2.2-fold higher risk of shingles with Janus kinase inhibitors than with tumour necrosis factor antagonists, anti-integrin agents and anti-interleukin agents [1]. This is clinically important because small molecules are increasingly used after biologic exposure. One point merits further emphasis. The main question for Asian practice is not whether Janus kinase inhibition can increase shingles risk, but whether the absolute risk and comparative hierarchy observed in a claims-based cohort are directly transportable to East Asian healthcare settings. Herpes zoster risk with tofacitinib in ulcerative colitis appears sensitive to patient and regional factors. In the long-term ulcerative colitis clinical programme, herpes zoster incidence rates with tofacitinib were 3.38 and 3.30 per 100 patient-years in the overall cohorts, and older age, lower body weight, geographic region and prior tumour necrosis factor inhibitor failure were identified as risk factors [2]. A dedicated East Asian OCTAVE Open analysis reported a herpes zoster incidence rate of 6.07 per 100 patient-years, numerically higher than the global study population [3]. Real-world Asian comparative data are also not fully concordant with Western comparative estimates. In a Korean nationwide study of moderate-to-severe ulcerative colitis, the risk of opportunistic infections, including herpes zoster and tuberculosis, did not differ significantly between tofacitinib and anti-TNF inhibitor users [4]. Herpes zoster incidence was numerically higher with tofacitinib than with anti-TNF inhibitors, but the between-group difference was not statistically significant [4]. The authors explicitly discussed possible contributions from genetic background and vaccination practice [4]. This does not refute the findings of Ahuja et al., but it suggests that class-level hazard ratios may require local calibration before being used for counselling individual Asian patients. Background epidemiology further supports this caution. Korean population-based data show that inflammatory bowel disease itself is associated with increased herpes zoster risk [5]. In eastern China, a recent population-based cohort found an overall herpes zoster incidence of 4.77 per 1000 person-years and 16.13 per 1000 person-years among adults with increased-risk conditions, with rising standardised incidence from 2015 to 2021 [6]. Thus, local baseline risk, vaccine availability, vaccine uptake, corticosteroid exposure and treatment sequencing may all modify the absolute benefit of prevention. Future analyses would be strengthened by reporting race-specific and region-specific absolute rates, vaccination status, age, body weight, corticosteroid exposure and prior biologic failure across therapy classes. Until such data are available, the finding that Janus kinase inhibitors warrant careful shingles risk assessment is persuasive, but preventive counselling and vaccination timing should be adapted to local Asian epidemiology rather than extrapolated solely from pooled comparative estimates. Guofu Mao developed the concept and drafted the initial version. Haizhen Lan contributed to literature verification and critical revision. Both authors approved the final version. Guofu Mao: writing – original draft, writing – review and editing, conceptualization. Haizhen Lan: writing – original draft. Artificial Intelligence Disclosure: Artificial intelligence-assisted language editing was used during manuscript preparation. The authors reviewed and take full responsibility for the final content. The authors have nothing to report. The authors have nothing to report. The authors declare no conflicts of interest. This article is linked to Ahuja et al. paper. To view this article, visit https://doi.org/10.1111/apt.70418. No new data were generated or analysed in support of this correspondence.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: